Companies / Acrivon Therapeutics, Inc. / Activity
Activity — Acrivon Therapeutics, Inc.
24 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | RA Capital Management, L.P. Director | Grant | Common Stock | $7.00M | +3.9M +49.14% | 11,803,094 27.54% of shares | low |
| Jan 14, 2026 | Blume-Jensen Peter CEO | Buy | Common Stock | $82.1K | +49K +2.39% | 2,095,771 4.89% of shares | medium |
| Feb 21, 2026 | Blume-Jensen Peter CEO | Other | Common Stock | $21.8K | -14K -0.68% | 2,080,204 4.85% of shares | low |
| Jan 13, 2026 | Devroe Eric Executive | Buy | Common Stock | $17.2K | +10K +15.31% | 75,308 0.18% of shares | low |
| Jan 14, 2026 | Levy Adam D. Executive | Buy | Common Stock | $15.0K | +9K +72.69% | 20,983 0.05% of shares | low |
| Feb 14, 2026 | Blume-Jensen Peter CEO | Other | Common Stock | $2.1K | -1K -0.06% | 2,094,469 4.89% of shares | low |
| Jan 17, 2026 | Miller Mary Executive | Other | Common Stock | $1.3K | -659 -1.91% | 33,896 0.08% of shares | low |
| Feb 14, 2026 | Devroe Eric Executive | Other | Common Stock | $1.2K | -723 -0.96% | 74,585 0.17% of shares | low |
| Feb 14, 2026 | Blume-Jensen Peter CEO | Other | Common Stock | $944 | -579 -0.18% | 314,127 0.73% of shares | low |
| Feb 14, 2026 | Gamelin Erick Executive | Other | Common Stock | $768 | -471 -3.08% | 14,812 0.03% of shares | low |
| Feb 14, 2026 | Miller Mary Executive | Other | Common Stock | $354 | -217 -0.64% | 33,679 0.08% of shares | low |
| Feb 14, 2026 | Peterson Katharine Executive | Other | Common Stock | $189 | -116 -2.81% | 4,006 <0.01% of shares | low |
| May 18, 2026 | RA Capital Management, L.P. Director | Grant | Common Stock | $0 | +9K | 9,366 0.02% of shares | low |
| May 18, 2026 | Magovcevic-Liebisch Ivana Director | Grant | Common Stock | $0 | +9K | 9,366 0.02% of shares | low |
| Jun 17, 2026 | RA Capital Management, L.P. Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,275 0.05% of shares | low |
| Jun 17, 2026 | Magovcevic-Liebisch Ivana Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,275 0.05% of shares | low |
| Mar 1, 2026 | Miller Mary Executive | Grant | Stock Option (Right to Buy) | — | +130K | 129,760 0.30% of shares | low |
| Mar 1, 2026 | Peterson Katharine Executive | Grant | Stock Option (Right to Buy) | — | +32K | 31,900 0.07% of shares | low |
| Mar 1, 2026 | Mirza Mansoor Raza Executive | Grant | Stock Option (Right to Buy) | — | +174K | 174,068 0.41% of shares | low |
| Mar 1, 2026 | Levy Adam D. Executive | Grant | Stock Option (Right to Buy) | — | +133K | 132,925 0.31% of shares | low |
| Mar 1, 2026 | Gamelin Erick Executive | Grant | Stock Option (Right to Buy) | — | +95K | 94,946 0.22% of shares | low |
| Mar 1, 2026 | Devroe Eric Executive | Grant | Stock Option (Right to Buy) | — | +187K | 186,728 0.44% of shares | low |
| Mar 1, 2026 | Blume-Jensen Peter CEO | Grant | Stock Option (Right to Buy) | — | +185K | 185,495 0.43% of shares | low |
| Mar 1, 2026 | Blume-Jensen Peter CEO | Grant | Stock Option (Right to Buy) | — | +417K | 417,210 0.97% of shares | low |